

# Butorphic® Injection <sup>IV</sup> (Butorphanol Tartrate)



**Butorphic® (Butorphanol Tartrate) Injection is a totally synthetic centrally acting, narcotic agonist-antagonist analgesic with potent antitussive activity.**

## 10 mg/mL Sterile Injectable Solution

**INDICATIONS:** For the relief of pain associated with colic and postpartum pain in adult horses and yearlings.

Clinical studies in the horse have shown that butorphanol tartrate alleviates abdominal pain, associated with torsion, impaction, intussusception, spasmodic and tympanic colic, and postpartum pain. Butorphic is a potent analgesic, and should be used with caution with other sedative or analgesic drugs as these are likely to produce additive effects.

Each mL of Butorphic contains 10 mg butorphanol base (as butorphanol tartrate), 3.3 mg citric acid, 6.4 mg sodium citrate, 4.7 mg sodium chloride, and 0.1 mg benzethonium chloride, q.s, with water for injection.

Approved by FDA under ANADA #200-332; this product is considered a generic equivalent to the reference product, Tobugesic®.

### Available in:

- 20 mL and 50 mL multi-dose vials.



NDC 69043-064-05

## Butorphic® <sup>IV</sup> (butorphanol tartrate injection)

contains 10 mg butorphanol base per mL as butorphanol tartrate

**Caution:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Approved by FDA under ANADA # 200-332

Net Contents: 50 mL

**Cronus**  
Pharma

**Cronus**  
Pharma

For more information about Cronus Pharma products please contact your authorized distributor.

[www.cronuspharmausa.com](http://www.cronuspharmausa.com)

1 (844) 227-6687

Cronus Pharma LLC is a fully integrated R&D, manufacturing, and marketing animal health pharmaceutical company headquartered in East Brunswick, NJ. Dedicated to providing quality and cost-effective pharmaceuticals to the U.S. animal health market, our products are accessible to all veterinarians and pet owners through national and regional distributors.

**Please refer to the Package Insert for complete prescribing instructions, precautions, and full safety information.**

# BUTORPHIC® <sup>IV</sup>

## BUTORPHANOL TARTRATE INJECTION


100 mg/mL

Veterinary Injection For Intramuscular Use in Cats and Subhuman Primates Only

**CAUTION:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

**DESCRIPTION:** Butorphic (butorphanol tartrate injection) is a totally synthetic centrally acting, narcotic agonist-antagonist analgesic with potent antitussive activity. It is a member of the phenanthrene series. The chemical name is Morphinan-3, 14-diol, 17-(cyclobutylmethyl)-,(-)-, (S-(R\*,R\*))-2,3-dihydroxybutanedioate (1:1) (salt). It is a white, crystalline, water soluble substance having a molecular weight of 477.55; its molecular formula is  $C_{21}H_{29}NO_2 \cdot C_4H_6O_6$ .

**Chemical Structure:**



Each mL of Butorphic contains 10 mg butorphanol base (as butorphanol tartrate), 3.3 mg citric acid, 6.4 mg sodium citrate, 4.7 mg sodium chloride, and 0.1 mg benzethonium chloride, q.s. with water for injection.

**CLINICAL PHARMACOLOGY:**

**COMPARATIVE PHARMACOLOGY:** In animals, butorphanol has been demonstrated to be 4 to 30 times more potent than morphine and pentazocine (Talwin®-V) respectively.<sup>1</sup> In humans, butorphanol has been shown to have 5 to 7 times the analgesic activity of morphine and 20 times that of pentazocine.<sup>2,3</sup> Butorphanol has 15 to 20 times the oral antitussive activity of codeine or dextromethorphan in dogs and guinea pigs.<sup>4</sup>

As an antagonist, butorphanol is approximately equivalent to nalorphine and 30 times more potent than pentazocine.<sup>1</sup>

Cardiopulmonary depressant effects are minimal after treatment with butorphanol as demonstrated in dogs,<sup>5</sup> humans<sup>6,7</sup> and horses.<sup>8</sup> Unlike classical narcotic agonist analgesics which are associated with decreases in blood pressure, reduction in heart rate, and concomitant release of histamine, butorphanol does not cause histamine release.<sup>1</sup> Furthermore, the cardiopulmonary effects of butorphanol are not distinctly dosage related but rather reach a ceiling effect beyond which further dosage increases result in relatively lesser effects.


Reproduction: Studies performed in mice and rabbits revealed no evidence of impaired fertility or harm to the fetus due to butorphanol tartrate. In the female rat, parenteral administration was associated with increased nervousness and decreased care for the newborn, resulting in a decreased survival rate of the newborn. This nervousness was seen only in the rat species.

**EQUINE PHARMACOLOGY:** Following intravenous injection in horses, butorphanol is largely eliminated from the blood within 3 to 4 hours. The drug is extensively metabolized in the liver and excreted in the urine.

In ponies, butorphanol given intramuscularly at a dosage of 0.22 mg/kg was shown to alleviate experimentally induced visceral pain for about 4 hours.<sup>9</sup>

In horses, intravenous dosages of butorphanol ranging from 0.05 to 0.4 mg/kg were shown to be effective in alleviating visceral and superficial pain for at least four hours, as illustrated in the following figure:

### ANALGESIC EFFECTS OF BUTORPHANOL GIVEN AT VARIOUS DOSAGES IN HORSES WITH ABDOMINAL PAIN



\*Pain threshold in butorphanol-treated colicky horses relative to placebo controls

A definite dosage-response relationship was detected in that butorphanol dosage of 0.1 mg/kg was more effective than 0.05 mg/kg but not different from 0.2 mg/kg in alleviating deep abdominal pain.

**ACUTE EQUINE STUDIES:** Rapid intravenous administration of butorphanol at a dosage of 2.0 mg/kg (20 times the recommended dosage) to a previously unmedicated horse resulted in a brief episode of inability to stand, muscle fasciculation, a convulsive seizure of 6 seconds duration, and recovery within three minutes. The same dosage administered after 10 successive daily 1.0 mg/kg dosages of butorphanol resulted only in transient sedative effects. During the 10 day course of administration at 1.0 mg/kg (10 times the recommended use level) in two horses, the only detectable drug effects were transient behavioral changes typical of narcotic agonist activity. These included muscle fasciculation about the head and neck, dysphoria, lateral nystagmus, ataxia, and salivation. Repeated administration of butorphanol at 1.0 mg/kg (10 times the recommended dose) every four hours for 48 hours caused constipation in one of two horses

**SUBACUTE EQUINE STUDIES:** Horses were found to tolerate butorphanol given intravenously at dosages of 0.1, 0.3, and 0.5 mg/kg every 4 hours for 48 hours followed by once daily injections for a total of 21 days. The only detectable drug effects were slight transient ataxia observed occasionally in the high dosage group. No clinical, laboratory, or gross or histopathologic evidence of any butorphanol-related toxicity was encountered in the horses.

**INDICATIONS:** Butorphic (butorphanol tartrate injection) is indicated for the relief of pain associated with colic in adult horses and yearlings. Clinical studies in the horse have shown that butorphanol tartrate alleviates abdominal pain, associated with torsion, impaction, intussusception, spasmodic and tympanic colic, and postpartum pain.

**WARNINGS: DO NOT USE IN HORSES INTENDED FOR HUMAN CONSUMPTION. NOT FOR HUMAN USE.**

**CAUTION:** Butorphic, a potent analgesic, should be used with caution with other sedative or analgesic drugs as these are likely to produce additive effects.

There are no well-controlled studies using butorphanol in breeding horses, weanlings, and foals. Therefore, the drug should not be used in these groups.

**ADVERSE REACTIONS:** In clinical trials in horses, the most commonly observed side effect was slight ataxia which lasted 3 to 10 minutes. Marked ataxia was reported in 1.5% of the 327 horses treated. Mild sedation was reported in 9% of the horses.

**CONTACT INFORMATION:** To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Cronus Pharma LLC at 1-844-227-6687 (1-844-2-CRONUS).

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at [www.fda.gov/reportanimalae](http://www.fda.gov/reportanimalae)

**DOSAGE:** The recommended dosage in the horse is 0.1 mg of butorphanol per kilogram of body weight (0.05 mg/lb) by intravenous injection. This is equivalent to 5 mL of Butorphic for each 1000 lbs body weight. The dose may be repeated within 3 to 4 hours but treatment should not exceed 48 hours. Pre-clinical model studies and clinical field trials in horses demonstrate that the analgesic effects of butorphanol tartrate are seen within 15 minutes following injection and persist for about 4 hours.

**HOW SUPPLIED:** Butorphic (butorphanol tartrate injection), 10 mg base activity per mL.

NDC 69043-064-02 20 mL vial in package of one

NDC 69043-064-05 50 mL vial in package of one

**STORAGE:** Store at controlled room temperature 20°-25°C (68°-77°F), with excursions permitted between 15°-30°C (59°-86°F). Protect from light.

Use within 56 days of first puncture and puncture a maximum of 4 times for 20 mL fill and 10 times for 50 mL fill.

**REFERENCES:**

1. Pircio, A.W. et al: The Pharmacology of Butorphanol. *Arch. Int. Pharmacodyn. Ther.* 220(2):231-257, 1976.
2. Dobkin, A.B. et al: Butorphanol and Pentazocine in Patients with Severe Postoperative Pain. *Clin. Pharmacol. Ther.* 18:547-553, 1975.
3. Gilbert, M.S. et al: Intramuscular Butorphanol and Meperidine in Postoperative Pain. *Clin. Pharmacol. Ther.* 20:359-364, 1976.
4. Cavanagh, R.L. et al: Antitussive Properties of Butorphanol, *Arch. Int. Pharmacodyn. Ther.* 220 258- 268, 1976.
5. Shurig, J.E. et al: Effect of Butorphanol and Morphine on Pulmonary Mechanics, Arterial Blood Pressure, and Venous Plasma Histamine in the Anesthetized Dog. *Arch. Int. Pharmacodyn. Ther.* 233:296-304, 1978.
6. Nagashima, H. et al: Respiratory and Circulatory Effects of Intravenous Butorphanol and Morphine *Clin. Pharmacol. Ther.* 19:735-745, 1976.
7. Popio, K.A. et al. Hemodynamic and Respiratory Effects of Morphine and Butorphanol. *Clin. Pharm. Ther.* 23:281-287, 1978.
8. Robertson, J.T. and Muir, W.W.: Cardiopulmonary Effects of Butorphanol Tartrate in Horses. *Am. J. Vet. Res.* 42:41-44, 1981.
9. Kalpravidh, M. et al: Effects of Butorphanol, Flunixin, Levorphanol, Morphine, Pentazocine and Xylazine in Ponies. *Am. J. Vet. Res.* 45:217-223, 1984.

Manufactured for:

**Cronus Pharma LLC,**  
East Brunswick, NJ 08816.  
Contact No: 1-844-227-6687  
(1-844-2-CRONUS)  
Made in India

Code: 4206162/TS/DRUGS/2023

Revised: January 2025

Approved by FDA under ANADA # 200-332

PC064-00

